Filgotinib
As of the edition of 20 October 2026, Filgotinib is a small molecule: marketed, first approved in 2020 (EU); acts on JAK1, JAK2 and TYK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Jyseleca
- First approved
- 24 September 2020 (EU)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Gilead Sciences; 3 holders in all
- Registered trials
- 57, 10 stopped early
- Disease areas
- Bones, joints and muscles; Skin and connective tissue; Immune system; Digestive system; Eye; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Filgotinib.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 2 | 0 |
| Phase 1 | 11 | 10 | 0 | 1 |
| Phase 2 | 19 | 15 | 1 | 3 |
| Phase 3 | 18 | 7 | 4 | 6 |
| Phase 4 | 6 | 1 | 3 | 0 |
| All trials | 57 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Applicant and Lead sponsor of trials | 2016 to now |
| Alfasigma | Applicant and Lead sponsor of trials | 2017 to now |